Answers are grounded in this paper and cite their sources.
Retrospective analysis identified key risks in prostate cancer, suggesting combined use of pi-rads and psa enhances diagnostic precision.
Motivation: Prostate cancer diagnosis often relies on biopsies that carry risks, and traditional methods like PSA testing have limited accuracy. Goal(s): Combine PI-RADS v2.1 scoring with PSAD to reduce unnecessary procedures without missing clinically significant prostate cancer (csPCa). Approach: A retrospective analysis of 462 patients undergoing prostate biopsies; logistic regression identified independent risk factors; ROC curves evaluated diagnostic performance of the combined PI-RADS v2.1 score and PSAD. Results: PI-RADS v2.1 score and PSAD are independent risk factors for csPCa. Combining them improved diagnostic accuracy (AUC = 0.964), allowing safe avoidance of biopsies in certain cases. Impact: By integrating PI-RADS v2.1 scores with PSAD, this study offers a validated method to reduce unnecessary prostate biopsies by 40%, enhancing patient care and diagnostic precision for clinically significant prostate cancer.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: